Piedmont Investment Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Piedmont Investment Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,579	Closed	-$6K	–	2960
2018 Q2	$6K	Buy	+2,579	New	+$7.2K	﹤0.01%	2082
2017 Q1	–	Sell	-937	Closed	-$1.99K	–	705
2016 Q4	$1.99K	Hold	937	–	–	﹤0.01%	651
2016 Q3	$3.14K	Buy	937 +413	+79%	+$1.31K	﹤0.01%	400
2016 Q2	$1.65K	Hold	524	–	–	﹤0.01%	342
2016 Q1	$1.75K	Hold	524	–	–	﹤0.01%	337
2015 Q4	$1.85K	Hold	524	–	–	﹤0.01%	341
2015 Q3	$2.63K	Buy	524 +333	+174%	+$1.91K	﹤0.01%	305
2015 Q2	$1.23K	Hold	191	–	–	﹤0.01%	388
2015 Q1	$1.34K	Hold	191	–	–	﹤0.01%	298
2014 Q4	$1.47K	Hold	191	–	–	﹤0.01%	289
2014 Q3	$1.43K	Hold	191	–	–	﹤0.01%	283
2014 Q2	$1.85K	Hold	191	–	–	﹤0.01%	290
2014 Q1	$1.59K	Hold	191	–	–	﹤0.01%	304
2013 Q4	$1.61K	Buy	+191	New	+$1.61K	﹤0.01%	306

Other funds holding PDLI

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Piedmont Investment Advisors's PDLI Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q3 2018, closing a stake of 2,579 shares — an estimated $6K sold.

Piedmont Investment Advisors first reported a position in PDLI in Q4 2013 and held it in 14 quarters. The position peaked at $6K in Q2 2018. 152 funds tracked by Wall St. Rank hold PDLI as of Q3 2018.

Piedmont Investment Advisors reported no remaining PDL BioPharma, Inc. position as of Q3 2018 after selling out during the quarter.
Piedmont Investment Advisors sold 2,579 PDL BioPharma, Inc. shares in Q3 2018, an estimated $6K.
Piedmont Investment Advisors first reported a position in PDL BioPharma, Inc. in Q4 2013 and held it in 14 quarters.
Piedmont Investment Advisors's PDL BioPharma, Inc. position peaked at $6K in Q2 2018.
152 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.